.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Novartis
US Department of Justice
Harvard Business School
McKinsey
Fuji
Farmers Insurance
Fish and Richardson
Colorcon
Merck

Generated: January 22, 2018

DrugPatentWatch Database Preview

Details for Patent: ➤ Subscribe

« Back to Dashboard

Details for Patent: ➤ Subscribe

Title: Controlled release compositions including polyethylene oxide with urethane cross-linking
Abstract:A controlled release composition comprising an active substance other than a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1000 which comprises polyethylene oxide and are cross-linked through urethane groups.
Inventor(s): Embrey; Mostyn P. (Oxford, GB2), Graham; Neil B. (Dunbartonshire, GB6)
Assignee: National Research Development Corporation (London, GB2)
Filing Date:Jan 02, 1990
Application Number:07/459,959
Claims:1. A process for preparation of a controlled release composition comprising an active substance other than a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1,500 which comprise polyethylene oxide and are cross-linked through urethane groups the degree of cross-linking being such that there is at least one cross-linking point per ten residues comprising said polyethylene oxide but such that the preparation of said polyethylene oxide is greater than 50% by weight of the polymeric carrier, said process comprising fabricating said polymeric carrier; contacting said polymeric carrier with a solution of said active substance and permitting said carrier to swell therein; and removing the swollen polymeric carrier from said solution.

2. The process of claim 1, wherein said polymeric carrier removed from said solution is dried.

3. The process of claim 1, wherein the permitted swelling of said polymeric carrier is from 200 to 700 parts per volume per hundred of the initial dry volume.

4. The process of claim 1, wherein the swelling is effected at a temperature of -20.degree. C. to +20.degree..
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Medtronic
Fish and Richardson
McKesson
Deloitte
Mallinckrodt
Cerilliant
Teva
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2018 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot